This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
Hong Kong, Shatin, NT, Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Seoul, Korea, South Korea
Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)
Time frame: at screening and at completion of every 6 weeks prior to the next dose administration
Time to progression
Time frame: at screening and at completion of every 6 weeks prior to the next dose administration
Overall survival
Time frame: at screening and at completion of every 6 weeks prior to the next dose administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Taipei, Taiwan ROC, Taiwan
Novartis Investigative Site
Tai Chung Municipality, Taiwan